Day: March 19, 2025

Strength in both segments contributed to consolidated year-over-year revenue growth for Q4 2024 Consolidated revenue increased sequentially every quarter throughout 2024, reflecting the success of the Company’s transformation strategy to higher-growth markets Management expects double-digit consolidated revenue growth in 2025, driven by anticipated OSS segment revenue of over 20% and consolidated EBITDA break even for the year ESCONDIDO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) autonomy and sensor processing at the edge, reported results for the three- and twelve-month periods ended December 31, 2024. Comparisons for the three- and twelve-month...

MAYFIELD VILLAGE, OHIO, March 19, 2025 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended February 28, 2025:  February(millions, except per share amounts and ratios; unaudited) 2025   2024   ChangeNet premiums written $ 6,684     $ 5,720   17   %Net premiums earned $ 6,036     $ 5,129   18   %Net income $ 928     $ 737   26   %Per share available to common shareholders $ 1.58     $ 1.24   28   %Total pretax net realized gains (losses) on securities $ (110 )   $ 80   (238 ) %Combined ratio   82.6       86.8   (4.2 ) pts.Average diluted equivalent common shares   587.6       587.3   0   %  February(thousands; unaudited) 2025   2024   % ChangePolicies in Force          Personal Lines          Agency – auto 9,950   8,462   18Direct...

SHANGHAI, China, March 19, 2025 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024. DayOne Data Centers Limited (“DayOne”), previously known as GDS International or GDSI, completed and closed its Series B equity raise on December 31, 2024. At closing, GDS’s equity interest in DayOne was diluted from 52.7% to 35.6%. Accordingly, GDS deconsolidated DayOne as a subsidiary and recognized DayOne as an equity investee. In the consolidated financial statements for the quarter and year ended December 31, 2024, DayOne’s operational results and cash flows have been excluded from the Company’s financial...

~ Q4 Comparable Store Sales increased 2.8% ~ ~ Q4 Earnings per Share and Adjusted Earnings per Share were $1.11 and $1.19 ~ ~ Targeting 75 New Store Openings for Fiscal 2025 ~ HARRISBURG, Pa., March 19, 2025 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the fourth quarter and full-year fiscal 2024. Fourth Quarter Summary:Total net sales increased 2.8% to $667.1 million. Excluding the impact of the 53rd week in fiscal 2023, net sales increased 8.5%. Net sales in the 53rd week of fiscal 2023 were $34.0 million and contributed approximately $0.04 to diluted earnings per share. Comparable store sales increased 2.8% from the prior year increase of 3.9%. The Company opened 13 new stores, ending the quarter with 559 stores in 31 states, an increase of 9.2%...

Full Year 2024 HighlightsRevenue increased 26% to €1,107 million Profit for the period of €34 million was in-line with prior year Adjusted EBITDA1 increased 33% to €222 million and Adjusted EBITDA margin1 expanded to 20.1% Net cash from operating activities increased 36% to €353 million and Free cash flow1 increased 133% to €118 million Customer Net Retention Rate1 increased to 127% Implemented $200 million share repurchase plan and purchased $20.3 million under the plan Exceeded full year guidance for both revenue and Adjusted EBITDA Acquired affiliate marketing assets of XLMedia PLCFourth Quarter 2024 HighlightsRevenue increased 22% to €307 million Loss for the period of €1 million primarily due to foreign currency fluctuations Adjusted EBITDA1 increased 53% to €61 million and Adjusted EBITDA margin1 expanded to 19.7% Net cash...

65% oncology products revenue growth drove profitable operation and supported new ATTC platform HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:​13; Nasdaq/AIM:​HCM) today reports its financial results for the year ended December 31, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 12:00 noon GMT / 8:00 p.m. HKT in English on Wednesday, March 19, 2025, and tomorrow at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, March 20, 2025. After registration, investors may access the live webcast via HUTCHMED’s website at www.hutch-med.com/event. All amounts are expressed in US dollars unless otherwise stated. Global commercial progress and delivery of sustainable...

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. “2024 was a pivotal year for MediWound, marked by strong execution, clinical progress, and strategic collaborations,” said Ofer Gonen, CEO of MediWound. “The initiation of the VALUE Phase III pivotal study is another major...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx) Company to host webcast today at 8:30 a.m. ETMORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the full year ended December 31, 2024. The company will also host a webcast at 8:30 a.m. ET on March 19, 2025 to discuss its financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Building...